Early oseltamivir initiation and influenza outcomes in kidney transplant recipients: a multicenter real-world study.
12 affiliations
- 1Department of Clinical Pharmacy, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 31000, China.
- 2Hangzhou Linping District Integrated Traditional Chinese and Western Medicine Hospital, Hangzhou, China.
- 3The Second People's Hospital of Shanxi Province, Taiyuan, China.
- 4National Alliance of Transplant Pharmacists, Zhejiang, China.
- 5Beijing Friendship Hospital Affiliated to Capital Medical University, Beijing, China.
- 6The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
- 7The First Affiliated Hospital, Sun Yat-sen Univeristy, Guangzhou, China.
- 8Union Hospital, Tongji Medical College, Huazhong University of Science, Wuhan, China.
- 9The First Affiliated Hospital of Soochow University, Suzhou, China.
- 10The First People's Hospital of Changzhou, Changzhou, China.
- 11Department of Clinical Pharmacy, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 31000, China. [email protected].
- 12National Alliance of Transplant Pharmacists, Zhejiang, China. [email protected].
Abstract
Background
Influenza infection poses a significant clinical threat to kidney transplant recipients due to their immunocompromised status. Although current guidelines recommend early antiviral therapy, real-world evidence supporting the effectiveness of oseltamivir, particularly regarding the optimal timing of initiation in this vulnerable population remains scarce.Objective
To identify independent factors associated with clinical improvement and time to symptom resolution in kidney transplant recipients infected with the influenza virus and treated with oseltamivir.Methods
We conducted a multicenter retrospective study enrolling adult kidney transplant recipients diagnosed with influenza virus infection across five centers between October 2023 and March 2024. Clinical outcomes were assessed using a validated Composite Symptom Score (range: 0-21) based on seven typical influenza symptoms. Clinical improvement was defined as achieving a score of ≤ 1 on the fifth day after oseltamivir initiation. Univariable and multivariable logistic regression analyses were performed to identify factors independently associated with clinical improvement, and linear regression was used to evaluate factors influencing time to symptom resolution. Given the small number of events, the multivariable logistic model was estimated using Firth's penalized likelihood method and restricted to two core predictors.Results
A total of 58 kidney transplant recipients were included. After one course of oseltamivir, 46 patients (79.3%) achieved clinical improvement. Compared with the improved group, patients without improvement had a significantly lower rate of early oseltamivir initiation (≤ 48 h: 58.3% vs. 84.8%, P = 0.044) and tended to present with higher baseline symptom scores. In multivariable logistic regression, oseltamivir initiation > 48 h was the only factor independently and significantly associated with reduced likelihood of clinical improvement (adjusted OR = 0.16, 95% CI: 0.03-0.76, P = 0.030), after adjusting for onset symptom score using Firth's penalized likelihood logistic regression to account for the small number of events. Higher baseline onset symptom score was also significantly associated with unfavorable outcomes (adjusted OR = 0.77, 95% CI: 0.63-0.91, P = 0.007). Consistently, multivariable linear regression confirmed that late oseltamivir initiation was independently associated with prolonged time to symptom resolution (β = 5.02, 95% CI: 3.00-7.04, P < 0.001). Neither dosage adjustment nor treatment duration extension was significantly associated with clinical outcomes.Conclusion
In this multicenter real-world study, early oseltamivir initiation (≤ 48 h) was the strongest independent predictor of both clinical improvement and a shorter symptom resolution time in kidney transplant recipients with influenza. Baseline disease severity showed a trend-level association with unfavorable outcomes, suggesting a narrowing "window of opportunity" for a therapeutic response in patients with a higher symptom burden. These findings reinforce the critical importance of prompt antiviral intervention in immunocompromised transplant recipients and provide real-world evidence to support clinical decision-making for early treatment prioritization.
Related
- Efficacy and safety of Lianhua Qingwen versus oseltamivir in children with influenza: a multicenter, randomized, double-blind, positive parallel-controlled study
- Changes in Tacrolimus and Everolimus Trough Concentrations and Dose Requirements After Initiation and Discontinuation of Letermovir Prophylaxis in Kidney Transplant Recipients: A Single-Center Retrospective Study
- Incidence and Outcomes of Human Adenovirus Infection and Disease in a Multicenter Cohort of Pediatric Allogeneic Hematopoietic Cell Transplant Recipients
- Immunosuppressive therapy management during sepsis in kidney transplant recipients: a prospective multicenter study
- The infectious disease burden in kidney transplant recipients: a 20-year multicenter cohort study on non-graft-failure hospitalizations in eastern China
BibTeX
@article{zhou2026early,
title = {{Early oseltamivir initiation and influenza outcomes in kidney transplant recipients: a multicenter real-world study.}},
author = {Yongting Zhou and Liang Yu and Jianping Wang and Wenjing Hou and Bangqin Hu and Pan Chen and Fang Zeng and Yan Zhang and Qing Qian and Kuifen Ma},
journal = {BMC infectious diseases},
year = {2026},
month = aug,
doi = {10.1186/s12879-026-14013-y},
url = {https://europepmc.org/article/MED/43009834},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Early oseltamivir initiation and influenza outcomes in kidney transplant recipients: a multicenter real-world study.
AU - Yongting Zhou
AU - Liang Yu
AU - Jianping Wang
AU - Wenjing Hou
AU - Bangqin Hu
AU - Pan Chen
AU - Fang Zeng
AU - Yan Zhang
AU - Qing Qian
AU - Kuifen Ma
PY - 2026
DA - 2026/08/13
JO - BMC infectious diseases
DO - 10.1186/s12879-026-14013-y
UR - https://europepmc.org/article/MED/43009834
AB - Background Influenza infection poses a significant clinical threat to kidney transplant recipients due to their immunocompromised status. Although current guidelines recommend early antiviral therapy, real-world evidence supporting the effectiveness of oseltamivir, particularly regarding the optimal timing of initiation in this vulnerable population remains scarce.Objective To identify independent factors associated with clinical improvement and time to symptom resolution in kidney transplant recipients infected with the influenza virus and treated with oseltamivir.Methods We conducted a multicenter retrospective study enrolling adult kidney transplant recipients diagnosed with influenza virus infection across five centers between October 2023 and March 2024. Clinical outcomes were assessed using a validated Composite Symptom Score (range: 0-21) based on seven typical influenza symptoms. Clinical improvement was defined as achieving a score of ≤ 1 on the fifth day after oseltamivir initiation. Univariable and multivariable logistic regression analyses were performed to identify factors independently associated with clinical improvement, and linear regression was used to evaluate factors influencing time to symptom resolution. Given the small number of events, the multivariable logistic model was estimated using Firth's penalized likelihood method and restricted to two core predictors.Results A total of 58 kidney transplant recipients were included. After one course of oseltamivir, 46 patients (79.3%) achieved clinical improvement. Compared with the improved group, patients without improvement had a significantly lower rate of early oseltamivir initiation (≤ 48 h: 58.3% vs. 84.8%, P = 0.044) and tended to present with higher baseline symptom scores. In multivariable logistic regression, oseltamivir initiation > 48 h was the only factor independently and significantly associated with reduced likelihood of clinical improvement (adjusted OR = 0.16, 95% CI: 0.03-0.76, P = 0.030), after adjusting for onset symptom score using Firth's penalized likelihood logistic regression to account for the small number of events. Higher baseline onset symptom score was also significantly associated with unfavorable outcomes (adjusted OR = 0.77, 95% CI: 0.63-0.91, P = 0.007). Consistently, multivariable linear regression confirmed that late oseltamivir initiation was independently associated with prolonged time to symptom resolution (β = 5.02, 95% CI: 3.00-7.04, P < 0.001). Neither dosage adjustment nor treatment duration extension was significantly associated with clinical outcomes.Conclusion In this multicenter real-world study, early oseltamivir initiation (≤ 48 h) was the strongest independent predictor of both clinical improvement and a shorter symptom resolution time in kidney transplant recipients with influenza. Baseline disease severity showed a trend-level association with unfavorable outcomes, suggesting a narrowing "window of opportunity" for a therapeutic response in patients with a higher symptom burden. These findings reinforce the critical importance of prompt antiviral intervention in immunocompromised transplant recipients and provide real-world evidence to support clinical decision-making for early treatment prioritization.
SN - 1471-2334
ER -